Skip to main content
The MSF patient support team navigates overcrowded and narrow alleys of Barangay 105 Aroma neighbourhood, Barangay 105, of Tondo, Manila, the Philippines, March 2, 2023.
The MSF patient support team navigates overcrowded and narrow alleys of Barangay 105 Aroma neighbourhood of Tondo, Manila. Philippines, March 2023.
© Ria Kristina Torrente

Children with tuberculosis need a shorter treatment regimen rolled out now

The MSF patient support team navigates overcrowded and narrow alleys of Barangay 105 Aroma neighbourhood of Tondo, Manila. Philippines, March 2023.
© Ria Kristina Torrente
  • Governments, donors, and global health partners must implement the World Health Organization-recommended four-month treatment regimen for children with tuberculosis.
  • An MSF study demonstrates the effectiveness of this shorter regimen, as well as its reduced burden of care on children, their families, and health systems.

Rio de Janeiro — Médecins Sans Frontières (MSF) released the outcomes from a study conducted in Uganda and the Philippines at the Union World Conference on Lung Health in Rio de Janeiro, Brazil. The results show that the World Health Organization (WHO)-recommended four-month treatment for children with non-severe tuberculosis (TB) can be successfully rolled out in routine general healthcare settings. MSF calls on governments, donors, and global health partners to move beyond policy adoption and accelerate the implementation of this child-friendly treatment regimen, while strengthening diagnosis, prevention, and care for all children affected by TB.

The study demonstrates that up to 74 per cent of children with TB overall, and up to 89 per cent in general healthcare settings, are eligible for the shorter regimen, with implementation being feasible and high treatment success rates. This would offer a more person-centred approach to care while reducing the burden of treatment on children, their families, and health systems.

Despite WHO recommending the four-month regimen since 2022, uptake has been slow in many countries with high TB burden. One important challenge has been the need to identify children with non-severe TB1 who can safely benefit from this shorter treatment, a process that requires clinical assessment and, where available, chest x-ray evaluation. Our new findings provide practical evidence that these challenges can be overcome in routine programme settings.

Children eligible for the four-month treatment regimen, according to our study:

“The four-month treatment regimen for children with non-severe, drug-susceptible TB2 uses the same medicines, including child-friendly formulations, but substantially reduces the burden on children and caregivers,” says Valentina Carnimeo, principal investigator for MSF’s multi-country TB study. 

“Fewer months of treatment means fewer clinic visits, less disruption to family life, lower costs for caregivers and health systems, and fewer days exposed to potential adverse effects,” says Carnimeo. “The evidence is clear: countries can confidently implement this regimen in routine care, and children should not have to wait longer to benefit from it.”  

In this prospective study involving 214 children receiving care in health facilities in Uganda and the Philippines, nearly three-quarters (74 per cent) were identified as eligible for the four-month regimen at the start of treatment. Treatment outcomes were highly positive, with 95 per cent of children successfully completing treatment. Healthcare workers and caregivers welcomed the shorter treatment, citing fewer clinic visits and a reduced burden on families. However, challenges remain, including limited access to chest x-rays, gaps in healthcare worker training, and high staff turnover.

“Our experience of implementing the four-month TB treatment regimen for children shows that it can be successfully introduced into routine care, leaving no reason to delay its wider rollout,” says Dr Maria Namulwana, study coordinator for MSF and Epicentre in Uganda. “But to make this a reality for more children, governments must go beyond updating guidelines and invest in training healthcare workers, strengthening diagnostic services, ensuring access to child-friendly medicines, and supporting families throughout treatment.”

Our experience of implementing the four-month TB treatment regimen for children shows that it can be successfully introduced into routine care, leaving no reason to delay its wider rollout. Dr Maria Namulwana, study coordinator for MSF and Epicentre in Uganda

TB remains the world's deadliest infectious disease, with children being hit hard. WHO’s 2026 Global TB Report estimated that among children with TB under five years old, half did not receive diagnosis and thus could not access treatment,3 a statistic that has not improved from previous years.

“Every three minutes, a child dies of TB,” says Dr Ana Paula Cavalheiro, leader of global TB platform of MSF. “We cannot keep leaving children behind when effective medical tools are already within reach, including reducing treatment duration for children with non-severe TB from six months to four months.

“It is high time governments and donors step up and ensure that children can be diagnosed early and receive the best possible treatment and care, no matter where they live,” says Dr Cavalheiro.

Notes for editors

The WHO-recommended four-month regimen for children with non-severe, drug-susceptible TB consists of two months of isoniazid, rifampicin and pyrazinamide, with or without ethambutol, followed by two months of isoniazid and rifampicin (2HRZ(E)/2HR). It uses the same medicines as the standard six-month regimen (2HRZ(E)/4HR), including child-friendly dispersible tablets.

MSF has been working to improve TB care for children in 12 countries, through our Test, Avoid and Cure TB in Children (TACTiC) initiative, by putting the latest WHO recommendations into practice and generating evidence to support their wider adoption.

  • Non-severe tuberculosis is a milder form of tuberculosis where the disease is limited and has not caused extensive damage to the lungs or spread widely in the body. 

  • Drug susceptible tuberculosis is a form of tuberculosis that responds to the standard first line medications and is not resistant to key drugs.